Title of article :
Severe Drug-Induced Liver Injury fromCombination Encorafenib/Binimetinib
Author/Authors :
Sundararajan, Srinath Division of Hematology-Oncology - Department of Medicine - University of Arizona Cancer Center - Tucson - AZ, USA , Gravbrot, Nicholas Division of Hematology-Oncology - Department of Medicine - University of Arizona Cancer Center - Tucson - AZ, USA
Abstract :
Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However,significant liver injury has not been demonstrated in the literature. Here, we report thefirst case of severe hepatic injuryassociated with encorafenib/binimetinib in a 58-year-old gentleman requiring admission and extensive workup. He wassuccessfully treated by withdrawing the combination therapy, and liver function returned to normal range
Keywords :
Severe Drug-Induced Liver Injury , Combination Encorafenib/Binimetinib , BRAF/MEK
Journal title :
Case Reports in Oncological Medicine
